Document ID: chunk:federal_register_of_legislation:F2025C00036:front:0:p7
Version: federal_register_of_legislation:F2025C00036
Segment Type: other
Provision Reference: 
Character Range: 17975–21482

waivers in relation to certain designations
Division 6—Transitional provisions relating to the Therapeutic Goods Legislation Amendment (2017 Measures No. 2) Regulations 2017
57 Definitions
58 Application—statements in relation to unapproved medicines and biologicals
59 Transitional—approval of form for statements
Division 7—Application and saving provisions relating to the Therapeutic Goods Legislation Amendment (2018 Measures No. 1) Regulations 2018
60 Application provisions
61 Operation of Schedule 2—complementary medicines
62 Saving provision
Division 8—Transitional provisions relating to the Therapeutic Goods Legislation Amendment (Exempt Devices and Goods) Regulations 2018
63 Application of amendments
Division 9—Transitional provisions relating to the Therapeutic Goods Legislation Amendment (2018 Measures No. 2) Regulations 2018
64 Definitions
65 Transitional provisions—exemptions from Parts 3‑2 and 3‑2A of the Act
66 Transitional provisions—exemptions from Part 3‑3 of the Act
Division 10—Application provisions relating to the Therapeutic Goods Legislation Amendment (2018 Measures No. 3) Regulations 2018
67 Application
Division 11—Application and transitional provisions relating to the Therapeutic Goods Amendment (Fees for Relisted Medicine) Regulations 2019
68 Application and transitional provisions
Division 12—Application and transitional provisions relating to the Therapeutic Goods Legislation Amendment (2019 Measures No. 1) Regulations 2019
Subdivision A—Definitions
69 Definitions
Subdivision B—Faecal microbiota transplant products
70 Faecal microbiota transplant products—Division 4 of Part 3‑2A of the Act
71 Faecal microbiota transplant products—Part 3‑3 of the Act
Subdivision C—Consumer medicine information documents
72 Consumer medicine information documents
Subdivision D—Handling and testing of samples
73 Handling and testing of samples
Subdivision E—Fee waivers and refunds for certain requests relating to prescription opioids
74 Fee waivers and refunds for certain requests relating to prescription opioids
Subdivision F—Clinical trials
75 Clinical trials
Division 13—Application and saving provisions relating to the Therapeutic Goods Legislation Amendment (2020 Measures No. 1) Regulations 2020
76 Approving supply of therapeutic goods under authorised prescriber scheme
77 Preliminary assessment of applications for variation of permissible ingredients determination
Division 15—Application provisions relating to the Minamata Convention on Mercury (Consequential Amendments) Regulations 2021
79 Application of amendments made by the Minamata Convention on Mercury (Consequential Amendments) Regulations 2021
Division 16—Application provisions relating to the Therapeutic Goods Legislation Amendment (2021 Measures No. 3) Regulations 2021
81 Access to medicines in emergency situations
82 Consumer medicine information documents
83 Approving supply of therapeutic goods under authorised prescriber scheme
Division 17—Application provisions relating to the Therapeutic Goods Legislation Amendment (2021 Measures No. 4) Regulations 2021
84 Amendments made by Division 1 of Part 2 of Schedule 1
85 Amendments made by Division 2 of Part 2 of Schedule 1
Division 18—Application provisions relating to Schedule 1 to the Therapeutic Goods Legislation Amendment (2022 Measures No. 1) Regulations 2022
86 Extemporaneously‑compounded medicinal cannabis products
Division 19—Application provisions relating to Schedule 2 to the Therapeutic Goods Legislation Amendment